Recent Company News

• 07:00 AM ET Jul 20, 2026
  

  BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

• 07:17 AM ET Jul 08, 2026
  

  BioLineRx and Hemispherian announce new preclinical data demonstrating strong synergistic effect between GLIX1 and PARP inhibitor in a PDX model of ovarian cancer (2.00a, 0.00)

• 07:00 AM ET Jul 08, 2026
  

  BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

• 07:08 AM ET May 22, 2026
  

  BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (1.00a, 0.00)

• 07:07 AM ET May 19, 2026
  

  BioLineRx, Hemispherian report promising preclinical results supporting Phase 1/2a trial of GLIX1 in recurrent GBM and high-grade gliomas (1.00a, 0.00)

• 07:04 AM ET Apr 28, 2026
  

  BioLineRx and Hemispherian announce first patient dosed in Phase 1/2a study of GLIX1 for the treatment of GBM (1.00a, 0.00)

• 07:04 AM ET Mar 26, 2026
  

  BioLineRx initiates first-in-human, Phase 1/2a study of GLIX1 for treatment of recurrent and progressive GBM and other high-grade glioma (1.00a, 0.00)

• 09:30 AM ET Mar 23, 2026
  

  Transcript Intelligence: BioLineRx Q4 Earnings Guidance